SCHEMBL15570404

SCHEMBL15570404

c1ccc(C2CCS2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.46
SLC18A3 Q16572 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
TSHR P16473 1/20 0.39
MAOA P21397 6/20 0.37
MAOB P27338 6/20 0.37
KDM1A O60341 4/20 0.37
CYP2C19 P33261 4/20 0.37
CYP2B6 P20813 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C9 P11712 2/20 0.37
LMNA P02545 1/20 0.37
CYP3A4 P08684 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
CYP2A6 P11509 1/20 0.37
SLC6A2 P23975 1/20 0.37
HTR2C P28335 1/20 0.37
ADRA1A P35348 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951171 0.88 BRD4 (0.43) BRD4SLC18A3SIGMAR1TSHRMAOA
SCHEMBL9340634 0.86 BRD4 (0.42) BRD4SLC18A3SIGMAR1
SCHEMBL10767082 0.84 BRD4 (0.41) BRD4SLC18A3MAOAMAOBKDM1A
SCHEMBL14275759 0.81 MAOB (0.42) BRD4SIGMAR1MAOAMAOBKDM1A
SCHEMBL31322216 0.81 SLC18A3 (0.53) BRD4SLC18A3SIGMAR1MAOAMAOB
SCHEMBL7402707 0.78 BRD4 (0.54) BRD4MAOBKDM1ACYP2D6HTR1A
SCHEMBL383636 0.78
SCHEMBL28529394 0.78
SCHEMBL513026 0.77 TSHR (0.38) BRD4TSHRMAOAMAOBKDM1A
SCHEMBL13221168 0.77 BRD4 (0.36) BRD4SLC18A3SIGMAR1TSHRMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110396114-A A kind of synthetic method of N- diaryl phosphinyl sulphoxide imine UNIV CHENGDU TECHNOLOGY 2019-11-01 CN disclosed
US-9290517-B2 Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives MERCK SHARP & DOHME CORP. (US) 2016-03-22 US disclosed
US-20150284411-A1 NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES MERCK SHARP & DOHME LLC 2015-10-08 US disclosed
EP-2888005-A1 NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES Merck Sharp & Dohme Corp. (US) 2015-07-01 EP disclosed
WO-2014031515-A1 NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2014-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284411-A1 NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES PRKAG2, PRKAB2, PRKAG1 BRD4 918/4885SLC18A3 4763/4885SIGMAR1 4750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.